MONTREAL, May 29, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today, further to its news release dated April 30, 2020, that as a result of the COVID-19 impact, Knight will continue to rely on the temporary relief afforded by DÉCISION N°2020-PDG-0023 of the Autorité des marchés financiers in respect of the obligation to file its first quarter 2020 financial results for the three-month period ended March 31, 2020 under National Instrument 51-102, Section 4.4. The Company confirms that it expects to file its first quarter 2020 financial results on June 26, 2020. In addition, the Company confirms that its management and other Company insiders are subject to an insider trading black-out policy that reflects the principles in section 9 of National Policy 11-207 Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions. Since the date of filing of Knight’s annual financial statements, there have been no material business developments in respect of the Company.